GUIDANT PIPELINE INCLUDES CORONARY STENTS, DIGITAL PTCA CATHETERS, IPO SAYS; LILLY DEVICE GROUP EXPECTS TO GROSS $246 MIL. IN INITIAL PUBLIC OFFERING
This article was originally published in The Gray Sheet
Executive Summary
Product development projects underway at Eli Lilly device company Guidant include a balloon-expandable stent for coronary uses and a line of coronary angioplasty catheters that incorporates digital inflation control, the company says in a prospectus for an initial public offering filed Sept. 13 with the Securities and Exchange Commission.
You may also be interested in...
There’s ‘No Silver Bullet’ For Making Medicines Packaging Sustainable
There’s no simple answer to the question of how to make medicines packaging sustainable, says international recycling consultancy and Veolia Group subsidiary Circpack. “Manufacturers need to assess what works best for them, and recyclers will do the same,” Circpack analyst and circular packaging expert Filipe Vieira de Castro tells HBW Insight in this exclusive Q&A. “The best thing we can all do is put effort into finding common ground between systems, which comes down to better understanding the complexities between them.”
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.